RESUMEN
A 33-year-old 20 weeks pregnant woman with severe abdominal pain in the past 1,5 hour visits the emergency department. MRI suggested an appendicitis. Laparoscopy showed an adnexal torsion. The right ovary was twisted back, and a good revascularization was observed shortly after. Patient was discharged one day post-surgery and had an uneventful pregnancy.
Asunto(s)
Abdomen Agudo , Enfermedades de los Anexos , Laparoscopía , Embarazo , Femenino , Humanos , Adulto , Enfermedades de los Anexos/cirugía , Anomalía Torsional/complicaciones , Anomalía Torsional/diagnóstico , Anomalía Torsional/cirugía , Dolor Abdominal/diagnóstico , Dolor Abdominal/etiología , Dolor Abdominal/cirugía , Abdomen Agudo/diagnóstico , Abdomen Agudo/etiología , OvarioRESUMEN
Vulvar squamous cell carcinoma (VSCC) comprises two distinct etiopathological subtypes: i) Human papilloma virus (HPV)-related VSCC, which arises via the precursor high grade squamous intraepithelial lesion (HSIL); and ii) HPV-independent VSCC, which arises via precursor, differentiated vulvar intraepithelial neoplasia (dVIN), driven by TP53 mutations. However, the mechanism of carcinogenesis of VSCC is poorly understood. The current study aimed to gain insight into VSCC carcinogenesis by identifying differentially expressed genes (DEGs) for each VSCC subtype. The expression of certain DEGs was then further assessed by performing immunohistochemistry (IHC) on whole tissue sections of VSCC and its precursors. Statistical analysis of microarrays was performed on two independent gene expression datasets (GSE38228 and a study from Erasmus MC) on VSCC and normal vulva. DEGs were identified that were similarly (up/down) regulated with statistical significance in both datasets. For HPV-related VSCCs, this constituted 88 DEGs, and for HPV-independent VSCCs, this comprised 46 DEGs. IHC was performed on VSCC (n=11), dVIN (n=6), HSIL (n=6) and normal vulvar tissue (n=7) with i) signal transducer and activator of transcription 1 (STAT1; an upregulated DEGs); ii) nuclear factor IB (NFIB; a downregulated DEG); iii) p16 (to determine the HPV status of tissues); and iv) p53 (to confirm the histological diagnoses). Strong and diffuse NFIB expression was observed in the basal and para-basal layers of normal vulvar tissue, whereas NFIB expression was minimal or completely negative in dVIN and in both subtypes of VSCC. In contrast, no discernable difference was observed in STAT1 expression among normal vulvar tissue, dVIN, HSIL or VSCC. By leveraging bioinformatics, the current study identified DEGs that can facilitate research into VSCC carcinogenesis. The results suggested that NFIB is downregulated in VSCC and its relevance as a diagnostic/prognostic biomarker deserves further exploration.
RESUMEN
Human papillomavirus (HPV) infections may result in benign hyperplasia, caused by low-risk HPV types, or (pre)malignant lesions caused by high-risk HPV types. The molecular basis of this difference in malignant potential is not completely understood. Here, we performed gene profiling of different HPV infected vulvar tissues (condylomata acuminata (n = 5), usual type vulvar intraepithelial neoplasia (uVIN) (n = 9)) and control samples (n = 14) using Affymetrix Human U133A plus 2 GeneChips. Data were analyzed using OmniViz®, Partek® and Ingenuity® Software. Results were validated by real-time RT-PCR and immunostaining. Although similarities were observed between gene expression profiles of low- and high-risk HPV infected tissues (e.g., absence of estrogen receptor in condylomata and uVIN), high-risk HPV infected tissues showed more proliferation and displayed more DNA damage than tissues infected with low-risk HPV. These observations were confirmed by differential regulation of cell cycle checkpoints and by increased expression of DNA damage-biomarkers p53 and γH2AX. Furthermore, FANCA, FANCD2, BRCA1 and RAD51, key players in the DNA damage response, were significantly upregulated (p < 0.05). In addition, we compared our results with publicly available gene expression profiles of various other HPV-induced cancers (vulva, cervix and head-and-neck). This showed p16(INK4a) was the most significant marker to detect a high-risk HPV infection, but no other markers could be found. In conclusion, this study provides insight into the molecular basis of low- and high-risk HPV infections and indicates two main pathways (cell cycle and DNA damage response) that are much stronger affected by high-risk HPV as compared to low-risk HPV.
Asunto(s)
Alphapapillomavirus , Puntos de Control del Ciclo Celular , Daño del ADN , Reparación del ADN , Infecciones por Papillomavirus/genética , Vulva/patología , Enfermedades de la Vulva/genética , Proteína BRCA1/biosíntesis , Biomarcadores de Tumor , Condiloma Acuminado/genética , Condiloma Acuminado/metabolismo , Condiloma Acuminado/patología , Condiloma Acuminado/virología , Inhibidor p16 de la Quinasa Dependiente de Ciclina/metabolismo , ADN Viral/análisis , ADN Viral/genética , Proteína del Grupo de Complementación A de la Anemia de Fanconi/biosíntesis , Proteína del Grupo de Complementación D2 de la Anemia de Fanconi/biosíntesis , Femenino , Perfilación de la Expresión Génica , Histonas/biosíntesis , Humanos , Infecciones por Papillomavirus/metabolismo , Infecciones por Papillomavirus/patología , Infecciones por Papillomavirus/virología , Recombinasa Rad51/biosíntesis , Proteína p53 Supresora de Tumor/biosíntesis , Vulva/virología , Enfermedades de la Vulva/patología , Enfermedades de la Vulva/virologíaRESUMEN
Vulvar lichen sclerosus and lichen planus are T-cell-mediated chronic skin disorders. Although autoimmunity has been suggested, the exact pathogenesis of these disorders is still unknown. Therefore, the aim of the current study was to investigate the molecular and immunological mechanisms critical to the pathogenesis of vulvar lichen sclerosus and lichen planus. By using gene expression profiling and real-time RT-PCR experiments, we demonstrated a significantly increased expression of the pro-inflammatory cytokines (IFNγ, CXCR3, CXCL9, CXCL10, CXCL11, CCR5, CCL4, and CCL5) specific for a Th1 IFNγ-induced immune response. In addition, BIC/microRNA-155 (miR-155)--a microRNA involved in regulation of the immune response--was significantly upregulated in lichen sclerosus and lichen planus (9.5- and 17.7-fold change, respectively). Immunohistochemistry showed a significant T-cell response, with pronounced dermal infiltrates of CD4(+), CD8(+), and FOXP3(+) cells. In conclusion, these data demonstrate an autoimmune phenotype in vulvar lichen sclerosus and lichen planus, characterized by increased levels of Th1-specific cytokines, a dense T-cell infiltrate, and enhanced BIC/miR-155 expression.
Asunto(s)
Enfermedades Autoinmunes/inmunología , Liquen Plano/inmunología , MicroARNs/inmunología , Células TH1/inmunología , Liquen Escleroso Vulvar/inmunología , Adulto , Anciano , Enfermedades Autoinmunes/metabolismo , Enfermedades Autoinmunes/patología , Citocinas/biosíntesis , Citocinas/genética , Citocinas/inmunología , Dermis/inmunología , Dermis/metabolismo , Femenino , Perfilación de la Expresión Génica , Humanos , Liquen Plano/metabolismo , Liquen Plano/patología , MicroARNs/biosíntesis , Persona de Mediana Edad , Linfocitos T/inmunología , Liquen Escleroso Vulvar/metabolismo , Liquen Escleroso Vulvar/patología , Adulto JovenRESUMEN
Imiquimod has been shown to be an effective treatment for usual type vulvar intraepithelial neoplasia (uVIN). Since local inflammation and burning are common side effects, patients often use nonsteroidal anti-inflammatory drugs (NSAIDs). Our study investigated whether NSAID-use, which has been documented to inhibit the cell-mediated immune response, interferes with the outcome of imiquimod treatment. Monocyte-derived dendritic cells (moDCs) and Langerhans cells (moLCs) were cultured in the presence of NSAIDs. The expression of relevant surface markers (CD80, CD86, CD40, HLA-DR, CCR6 and CCR7), stimulatory function, and cytokine production were evaluated. Furthermore, we analyzed in uVIN patients whether frequent NSAID-use had an effect on the clinical response and on immunocompetent cell counts before and after imiquimod treatment. Although an effect was observed on the expression of moDC and moLC maturation markers, NSAIDs did not affect the ability of moDCs and moLCs to stimulate allogeneic T-cell proliferation, or the production of cytokines in an allogeneic T-cell stimulation assay. In agreement with this, in uVIN patients treated with imiquimod, no interference of frequent NSAID-use with clinical outcome was observed. However, we did notice that high CD1a(+) and CD207(+) cell counts in frequent NSAID-users before treatment seemed to predict a favourable response to imiquimod treatment. Our data indicate that NSAID-use does not seem to interfere with moDC and moLC function and does not interfere with immunomodulatory properties of imiquimod in uVIN patients. Therefore, NSAIDs can safely be used to reduce imiquimod side effects in uVIN patients during treatment.
Asunto(s)
Aminoquinolinas/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Antineoplásicos/uso terapéutico , Carcinoma in Situ/tratamiento farmacológico , Neoplasias de la Vulva/tratamiento farmacológico , Biopsia , Carcinoma in Situ/inmunología , Separación Celular , Interacciones Farmacológicas , Femenino , Citometría de Flujo , Colorantes Fluorescentes , Humanos , Imiquimod , Inmunohistoquímica , Neoplasias de la Vulva/inmunologíaRESUMEN
OBJECTIVE: The aim of this retrospective clinical study was to evaluate clinical features, histopathology, treatment regimen, and follow-up in 95 patients with genital lichen planus. MATERIALS AND METHODS: We retrospectively analyzed data of 95 women diagnosed with genital lichen planus and visiting the vulvar clinic at Erasmus MC, Rotterdam, the Netherlands. RESULTS: All patients were symptomatic, most often complaining of vulvar soreness and burning (31.6%). Of all women, 34% had persistent symptoms for more than 5 years. On physical examination, 81.1% showed sharply demarcated erythematous lesions, usually located at the vestibule, and 56.8% had oral lesions. Treatment usually consisted of potent topical corticosteroids. Seventeen women (17.9%) were referred to the gynecology department for additional surgical treatment. In two of them, a vulvar squamous cell carcinoma was detected, followed by radical surgery. CONCLUSIONS: In cases with vulvar soreness and burning, sharply demarcated erythematous vulvar lesions, and the concomitant presence of oral lesions, the diagnosis of lichen planus should be considered and treatment must be initiated accordingly, even when histopathology is discordant.
Asunto(s)
Liquen Plano/tratamiento farmacológico , Liquen Plano/patología , Enfermedades de la Vulva/tratamiento farmacológico , Enfermedades de la Vulva/patología , Corticoesteroides/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Antiinflamatorios/uso terapéutico , Femenino , Histocitoquímica , Humanos , Liquen Plano/diagnóstico , Persona de Mediana Edad , Mucosa Bucal/patología , Países Bajos , Estudios Retrospectivos , Resultado del Tratamiento , Enfermedades de la Vulva/diagnósticoRESUMEN
Recently, we reported on the efficacy of imiquimod for treatment of usual type vulvar intraepithelial neoplasia (uVIN). A histologic regression of uVIN to normal tissue was observed in 58% of patients. As success of treatment is related to clearance of high-risk human papilloma virus (HPV), the aim of our study was to assess differences in immune cell counts and in the expression of p16(INK4a) in VIN tissue before and after imiquimod treatment, in relation to HPV clearance and clinical response. Vulvar tissue samples taken prior to imiquimod treatment and 4 weeks after treatment were tested for the presence of HPV. Previously determined immune cell counts (CD1a, CD207, CD208, CD123/CD11c, CD94, CD4, CD8 and CD25/HLA-DR) in epidermis and dermis of 25 VIN patients and 19 healthy controls were completed with the counts for CD14 and CD68. The expression of p16(INK4a) was investigated by immunohistochemistry in 15 patients. Before imiquimod treatment, both HPV cleared and HPV noncleared patients showed mainly in the dermis significantly upregulated immune cell counts compared to healthy controls. However, in patients that cleared HPV and showed histologic regression already 4 weeks after imiquimod treatment, immune cell counts and p16(INK4a) expression were normalized. In conclusion, our data indicate that imiquimod-induced clearance of HPV results in normalization of counts for certain immune cells and is strongly correlated with histologic regression of the disease.
Asunto(s)
Aminoquinolinas/uso terapéutico , Antineoplásicos/uso terapéutico , Carcinoma in Situ/inmunología , Recuento de Linfocitos , Papillomaviridae/efectos de los fármacos , Infecciones por Papillomavirus/inmunología , Neoplasias de la Vulva/inmunología , Adulto , Biomarcadores de Tumor/metabolismo , Carcinoma in Situ/tratamiento farmacológico , Carcinoma in Situ/virología , Estudios de Casos y Controles , Inhibidor p16 de la Quinasa Dependiente de Ciclina/metabolismo , ADN Viral/genética , Femenino , Humanos , Imiquimod , Técnicas para Inmunoenzimas , Persona de Mediana Edad , Infecciones por Papillomavirus/tratamiento farmacológico , Infecciones por Papillomavirus/virología , Reacción en Cadena de la Polimerasa , Pronóstico , Neoplasias de la Vulva/tratamiento farmacológico , Neoplasias de la Vulva/virología , Adulto JovenRESUMEN
BACKGROUND: A cleft of the lip with or without the palate (CLP) is a frequent congenital malformation with a heterogeneous etiology, for which folic acid supplementation has a protective effect. To gain more insight into the molecular pathways affected by natural folate, we examined gene expression profiles of cultured B-lymphoblasts from CLP patients before and after the addition of 5-methyltetrahydrofolate (5-mTHF) to the cultures. METHODS: Immortalized B-lymphoblasts from five children with CLP were cultured in folate-deficient medium for 5 days. 5-mTHF was added to a concentration of 30 nM. Gene expression patterns were then evaluated before and after supplementation using Human Genome U133 Plus 2.0 arrays. Data analysis was performed with Omniviz and the GEPAS analysis suite. Differential genes were categorized into biological pathways with Ingenuity Pathway systems. Differential expression was validated by quantitative RT-PCR. RESULTS: Using supervised clustering, with a false discovery rate <1%, we identified 144 and 409 significantly up-regulated and down-regulated probesets, respectively, after 5-mTHF addition. The regulated genes were involved in a variety of biological pathways, including one carbon pool and cell cycle regulation, biosynthesis of amino acids and DNA/RNA nucleotides, protein processing, apoptosis, and DNA repair. CONCLUSIONS: The large variety of the identified folate responsive pathways fits with the modifying role of folate via the methylation pathway. From the present data we may conclude that folate deficiency deranges normal cell development, which might contribute to the development of CLP. The role of these folate responsive genes in CLP development is intriguing and needs further investigation.
Asunto(s)
Labio Leporino/genética , Fisura del Paladar/genética , Ácido Fólico/fisiología , Perfilación de la Expresión Génica , Regulación del Desarrollo de la Expresión Génica/fisiología , Genoma Humano/fisiología , Transducción de Señal/genética , Línea Celular Transformada , Niño , Labio Leporino/metabolismo , Fisura del Paladar/metabolismo , Regulación hacia Abajo/genética , Femenino , Humanos , Masculino , Proyectos Piloto , Regulación hacia Arriba/genéticaRESUMEN
Usual type VIN is a premalignant disorder caused by persistent HPV infection. High prevalence of VIN in immuno-suppressed women suggests that a good innate and adaptive immune response is important for defense against HPV. Here, we explored expression levels of chemokines and related these to the presence or absence of immuno-competent cells (dendritic and T-cells) in affected (HPV-positive VIN) and non-affected (HPV-negative) vulvar tissues from the same patients. Combining microarray data with quantitative real-time RT-PCR, it was observed that several important chemokines were differentially expressed between VIN and control samples (up-regulation of IL8, CXCL10, CCL20 and CCL22 and down-regulation of CXCL12, CCL21 and CCL14). Furthermore, an increased number of mature dendritic cells (CD208+) seemed to be bottled up in the dermis, and although a T-cell response (increased CD4+ and CD8+ cells) was observed in VIN, a much larger response is required to clear the infection. In summary, it seems that most mature dendritic cells do not receive the proper chemokine signal for migration and will stay in the dermis, not able to present viral antigen to naive T-cells in the lymph node. Consequently the adaptive immune response diminishes, resulting in a persistent HPV infection with increased risk for neoplasia.
Asunto(s)
Alphapapillomavirus , Quimiocinas/metabolismo , Células Dendríticas/inmunología , Huésped Inmunocomprometido , Infecciones por Papillomavirus/complicaciones , Linfocitos T/inmunología , Infecciones Tumorales por Virus/complicaciones , Displasia del Cuello del Útero/inmunología , Neoplasias del Cuello Uterino/inmunología , Adulto , Quimiocinas/genética , Regulación hacia Abajo , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Inmunohistoquímica , Análisis por Micromatrices , Persona de Mediana Edad , Infecciones por Papillomavirus/metabolismo , Infecciones por Papillomavirus/virología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factores de Riesgo , Infecciones Tumorales por Virus/metabolismo , Infecciones Tumorales por Virus/virología , Regulación hacia Arriba , Neoplasias del Cuello Uterino/virología , Displasia del Cuello del Útero/virologíaRESUMEN
Tamoxifen is used as adjuvant treatment for postmenopausal breast cancer patients. The mechanism of action of tamoxifen in breast cancer patients is that tamoxifen inhibits growth of cancer cells by competitive antagonism for estrogens at the estrogen receptor (ER). In the endometrium, tamoxifen has an effect that varies with the ambient concentration of estrogen: in premenopausal women (high estrogen levels), tamoxifen displays an estrogen-antagonistic effect, while in postmenopausal women (low estrogen levels), tamoxifen displays an estrogen-agonistic mode of action. Here, using microarray technology we have compared estrogen signaling with tamoxifen signaling in the human endometrium. It was observed that on the one hand tamoxifen-treatment results in modulation of expression of specific genes (370 genes) and on the other hand tamoxifen-treatment results in modulation of a set of genes which are also regulated by estrogen treatment (142 genes). Upon focusing on regulation of proliferation, we found that tamoxifen-induced endometrial proliferation is largely accomplished by using the same set of genes as are regulated by estradiol. So, as far as regulation of proliferation goes, tamoxifen seems to act as estrogen agonist. Furthermore, tamoxifen-specific gene regulation may explain why tamoxifen-induced endometrial tumors behave more aggressively than sporadic endometrial tumors.
Asunto(s)
Endometrio/efectos de los fármacos , Endometrio/metabolismo , Estrógenos/metabolismo , Transducción de Señal/efectos de los fármacos , Tamoxifeno/farmacología , Análisis por Conglomerados , Femenino , Perfilación de la Expresión Génica , Regulación de la Expresión Génica , Humanos , Pólipos/patologíaRESUMEN
For the endometrium, estradiol and tamoxifen induce proliferation, and consequently, tamoxifen treatment of breast cancer results in a 2-fold to 7-fold increased risk for endometrial cancer. Here, the role of activation of growth factor receptor signaling in mediating the effects of estrogen and tamoxifen is determined. Microarray analysis of ECC-1 cells treated with estradiol or tamoxifen indicate that rapid responses to treatment (1 hour) are very distinct from long-term responses (>24 hours). Furthermore, estradiol and tamoxifen are observed to induce AKT activation. Comparing long-term estrogen- and tamoxifen-regulated genes with genes regulated by insulin-like growth factor 1 and amphiregulin reveals that the late effects of estrogen and tamoxifen signaling may partly be mediated via activation of growth factor receptor signaling pathways. It is hypothesized that both early and late effects of estrogen and tamoxifen signaling in the endometrium are partly mediated via the activation of growth factor receptor signaling, putatively at the level of AKT activation.
Asunto(s)
Endometrio/metabolismo , Estradiol/farmacología , Estrógenos/fisiología , Proteínas Proto-Oncogénicas c-akt/metabolismo , Receptores de Factores de Crecimiento/metabolismo , Tamoxifeno/farmacología , Línea Celular Tumoral , Endometrio/efectos de los fármacos , Receptores ErbB/metabolismo , Estrógenos/genética , Estrógenos/farmacología , Femenino , Perfilación de la Expresión Génica , Humanos , Factor I del Crecimiento Similar a la Insulina/metabolismo , Familia de Multigenes , Análisis de Secuencia por Matrices de Oligonucleótidos , Proteínas Proto-Oncogénicas c-akt/genética , Receptores de Factores de Crecimiento/genética , Transducción de SeñalRESUMEN
UNLABELLED: Vulvar intraepithelial neoplasia (VIN) is a premalignant disorder caused by human papillomaviruses. Basic knowledge about the molecular pathogenesis of VIN is sparse. Therefore, we have analyzed the gene expression profile of 9 VIN samples in comparison to 10 control samples by using genome wide Affymetrix Human U133A plus2 GeneChips. Results were validated by quantitative real-time RT-PCR analysis and immunostaining of a few representative genes (TACSTD1, CCNE2, AR and ESR1). Significance analysis of microarrays (SAM) showed that 1,497 genes were differentially expressed in VIN compared to controls. By analyzing the biological processes affected by the observed differences, we found that VIN appears to be a highly proliferative disease; many cyclins (CCNA, CCNB and CCNE) and almost all prereplication complex proteins are upregulated. Thereby, VIN does not seem to depend for its proliferation on paracrine or endocrine signals. Many receptors (for example ESR1 and AR) and ligands are downregulated. Furthermore, although VIN is not an invasive disease, the inhibition of expression of a marked number of cell-cell adhesion molecules seems to indicate development towards invasion. Upon reviewing apoptosis and angiogenesis, it was observed that these processes have not become significantly disregulated in VIN. IN CONCLUSION: although VIN is still a premalignant disease, it already displays several hallmarks of cancer.